Although some of these factors may be clinical surrogates for disease progression, the significance of absolute CD8+ cell counts in the peripheral blood provides new insight into LCT risk in SS and implicates potentially novel therapeutic approaches in management. This evidence concerns the gene CD8A and synovial sarcoma.